Concepedia

Author

Ludovic Gabellier

Centre Hospitalier Universitaire de MontpellierORCID

Also Known As

Edouard Forcade, Gabellier, Ludovic, Juliette Lambert, L. Gabellier, Ludovic Gabellier

65

Publications

200

Citations

9

H-Index

15

Concepts

All Affiliations

Centre Hospitalier Universitaire de MontpellierInsermCentre Hospitalier Universitaire de ToulouseUniversité de MontpellierCentre National de la Recherche Scientifique
LG

About

Ludovic Gabellier is an author at Centre Hospitalier Universitaire de Montpellier specializing in oncology, medicine, and neurovirology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

46

2

Health Sciences

1

1

25

3

Cell Biology

1

1

25

4

Immunology

1

1

21

5

Marrow Transplantation

1

1

25

Ludovic Gabellier

×

6

Publications

120

Citations

6

H-Index

YearCitations

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias

Rosa Paolillo, Mathias Boulanger, Pierre Gâtel,

Haematologica

2022

32

Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Klaus Hirschbühl, Myriam Labopin, Mohamed Houhou,

Bone Marrow Transplantation

2020

25

Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma

Jean‐Jacques Tudesq, Laure Vincent, Julie Lebrun,

Open Forum Infectious Diseases

2017

21

SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia

Ludovic Gabellier, Marion de Toledo, Mehuli Chakraborty,

Haematologica

2023

18

Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study

Antoine Bonnet, Céline Bossard, Ludovic Gabellier,

Cancer Medicine

2022

12

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A. Sallman,

Blood

2023

12

Page 1